ICICI Securities research report on Clean Science and Technology
Clean Science’s (CST) EBITDA grew only 5.5% YoY despite tailwinds of lower input prices, and HALS offtake. Its established products revenue has grown 8% YoY, while lower sales were due to weak demand for new products. HALS’ volumes were at 580te in Q1FY26 – far behind HALS’ FY26 guidance of 4kte; however, CST is now planning more complex series with over 2x realisation in HALS. The company is also in the process of ramping up/commissioning DHDT, BHT, barbituric acid and two performance products, which are expected to accelerate revenue growth.
Outlook
We cut our FY26–27E EPS by 2–3% and change our TP to INR 1,330 (vs. INR 1,360) with a FY27E P/E multiple of 35x (unchanged). Downgrade to REDUCE (from Hold). Promoter has announced a sizeable 24% reduction in its equity stake, which would bring their holding to 51% from the current 75%.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.